[HTML][HTML] Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
C Wilson, K Nicholes, D Bustos, E Lin, Q Song… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Epithelial to mesenchymal transition (EMT) is a key process in embryonic development and
has been associated with cancer metastasis and drug resistance. For example, in EGFR …
has been associated with cancer metastasis and drug resistance. For example, in EGFR …
[HTML][HTML] Restricting glutamine uptake enhances NSCLC sensitivity to third-generation EGFR-TKI almonertinib
Y Liu, X Ge, J Pang, Y Zhang, H Zhang, H Wu… - Frontiers in …, 2021 - frontiersin.org
The emergence of secondary resistance is the main failure cause of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung …
receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung …
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Abstract Purpose: HER2 (or ERBB2) aberrations, including both amplification and mutations,
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
have been classified as oncogenic drivers that contribute to 2% to 6% of lung …
[HTML][HTML] Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
SM Bokobza, Y Jiang, AM Weber, AM Devery… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR
M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the …
M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the …
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer
The potential therapeutic value of combinatorial regimens based on an EGF receptor
tyrosine kinase inhibitor (TKI) and autophagy inducing drugs was evaluated by comparing …
tyrosine kinase inhibitor (TKI) and autophagy inducing drugs was evaluated by comparing …
[HTML][HTML] Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy
FF Moreira-Leite, LR Harrison, A Mironov… - Journal of Thoracic …, 2010 - Elsevier
Introduction Non-small cell lung cancer (NSCLC) with certain activating mutations in the
epidermal growth factor receptor (EGFR) is sensitive to the small molecule EGFR tyrosine …
epidermal growth factor receptor (EGFR) is sensitive to the small molecule EGFR tyrosine …
Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells
H Hu, XW Zhang, L Li, MN Hu, WQ Hu, JY Zhang… - European Journal of …, 2021 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common cancer in the world. Gefitinib, an
inhibitor of EGFR tyrosine kinase, is highly effective in treating NSCLC patients with …
inhibitor of EGFR tyrosine kinase, is highly effective in treating NSCLC patients with …
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells
M Serizawa, M Kusuhara, V Zangiacomi… - Anticancer …, 2014 - ar.iiarjournals.org
Background/Aim: The acquisition of resistance to epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) remains a major challenge in lung cancer medicine. We …
tyrosine kinase inhibitors (TKIs) remains a major challenge in lung cancer medicine. We …
AZ1366: an inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non–small cell lung cancer cells following EGFR inhibition
HA Scarborough, BA Helfrich, M Casás-Selves… - Clinical Cancer …, 2017 - AACR
Purpose: The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has
provided novel treatment opportunities in EGFR-driven non–small cell lung cancer …
provided novel treatment opportunities in EGFR-driven non–small cell lung cancer …
[HTML][HTML] Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in …
J Sun, G Li, Y Liu, M Ma, K Song, H Li, D Zhu, XJ Tang… - Neoplasia, 2020 - Elsevier
Lung adenocarcinoma (LAD) is a human malignancy successfully treated with the tyrosine
kinase inhibitor (TKI) gefitinib; however, the enrichment of therapy resistant cancer stem …
kinase inhibitor (TKI) gefitinib; however, the enrichment of therapy resistant cancer stem …